R-CHOP is the standard regimen for patients with diffuse large B-cell lymphoma (DLBCL). However, the standard number of cycles is uncertain. Recently, interim PET/CT was found to predict prognosis in DLBCL. The hypothesis of this study is to optimize the number of cycles based on the interim results of PET/CT in order to avoid treatment exposure.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Previously untreated diffuse large B-cell lymphoma
Age range 18-80 years old
Eastern Cooperative Oncology Group performance status 0-2
Life expectancy of more than 3 months
Adequate organ function
You may not be if
Primary or secondary central nervous system involvement
Previous serious cardiac disease
History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
Pregnant or lactating women
Serious uncontrolled diseases and intercurrent infection